Dr. Hong Heng See

Keynote Speaker


N31, Centre for Sustainable and nanomaterials
Ibnu Sina Institute for Scientific & Industrial Research
Universiti Teknologi Malaysia
Johor Bahru, Malaysia

hhsee@utm.my / hhsee@ibnusina.utm.my


Title : An Integrated Lab-on-a-Chip Device for Point-of-Care Clinical Diagnostics

Abstract

In the clinical diagnostic, therapeutic drug monitoring (TDM) is commonly performed to determine the pharmaceutical drug concentrations in patients’ biological fluids in order to allow a close and timely control of their dosage. This practice is extremely important for a rapid medical intervention in case of toxicity-related issues and/or adjustment of drug dosage to improve the therapeutic demand. Nevertheless, TDM is usually performed in centralized laboratories equipped with bulky instruments, which restricts the application of TDM in real-time during point-of-care testing. Therefore, a new generation of diagnostic devices, capable of providing a rapid, sensitive and reliable diagnosis, is essential in order to avoid toxic side effects and enhance drug efficacy. Here, an integrated lab-on-a-chip portable system based on the microchip electrophoresis (MCE) coupled with an on-chip contactless conductivity detection (C4D) system was developed for the real-time determination of anticancer drugs, namely tamoxifen and its major metabolites, as well as glycopeptide antibiotics, namely the vancomycin compound present in the patient plasma samples. In brief, the integrated device consists of an MCE platform holding the double-T geometry glass microchip and connected to the high voltage sequencer and the C4D data system. The entire device is fully powered by an in-house 12 V DC output NiMH rechargeable battery pack. On the other hand, in order to enhance the detection sensitivity of targeted pharmaceutical drugs at the ultra-trace level in human plasma, a new online multi-stacking preconcentration technique based on field-enhanced sample injection and micelle-to-solvent stacking was developed and implemented in the developed lab-on-a-chip system. The linear detection range for tamoxifen and its metabolites as well the asvancomycin obtained successfully covered the entire therapeutic range in the patient plasma samples. The new analytical methodology shows great potential to be employed as a reliable real-time point-of-care diagnostic tool and exhibits advantages in terms of method simplicity, speed, detection sensitivity, and most importantly, portability.
KeywordsLab-on-a-chip; microchip electrophoresis; contactless conductivity detection; point-of-care; drug diagnostic




Copyright © SAMN2017